Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud (2022)

Peer-Reviewed Study · Hill A, Mirchandani M, Ellis L, Pilkington V · May 2022

Hill A et al., 2022-05: The corrected analysis by the authors of the retracted meta-analysis: of four prophylaxis trials, one was rated potentially fraudulent and three had high or uncertain risk of bias, leaving no significant prevention effect.

One was rated as being potentially fraudulent, two as having a high risk of bias and one as having some concerns for bias.

Hill A et al., 2022-05: The corrected analysis by the authors of the retracted meta-analysis: of four prophylaxis trials, one was rated potentially fraudulent and three had high or uncertain risk of bias, leaving no significant prevention effect. Meta-analysis with trial-quality subgrouping, 4 randomized trials of ivermectin for COVID-19 prevention; risk of bias by Cochrane RoB 2 plus raw-data checks where possible. Conclusion: ivermectin was not associated with prevention of RT-PCR-confirmed or symptomatic infection; the available prophylaxis trials are 'insufficient and of poor quality'. No conflict statement in the PubMed record. This is the replacement paper named in the retraction notice (IVE-45) and shows the same author group revising its own conclusion. Study type: review.